Table 1

Demographic and baseline characteristics

Anti-TNF-naiveAnti-TNF-IR
Secukinumab s.c.Secukinumab s.c.
150 mg (N=44)75 mg (N=45)Placebo (N=45)150 mg (N=28)75 mg (N=28)Placebo (N=29)
Age (years), mean (SD)43.7 (12.9)43.9 (14.1)43.5 (13.3)39.3 (11.6)45.2 (11.3)43.8 (13.2)
Female, n (%)18 (40.9)14 (31.1)10 (22.2)8 (28.6)8 (28.6)8 (27.6)
Race, n (%)
 White44 (100)42 (93.3)41 (91.1)25 (89.3)28 (100)29 (100)
 Asian03 (6.7)4 (8.9)2 (7.1)00
 American Indian or Alaskan Native0001 (3.6)00
Ethnicity, n (%)
 Hispanic/Latino03 (6.7)3 (6.7)5 (17.9)3 (10.7)5 (17.2)
 Not Hispanic/Latino40 (90.9)38 (84.4)36 (80.0)19 (67.9)21 (75.0)21 (72.4)
 Unknown or not reported4 (9.1)4 (8.9)6 (13.3)4 (14.3)4 (14.3)3 (10.3)
Weight (kg), mean (SD)80.4 (16.8)80.0 (18.3)81.8 (14.1)85.4 (19.6)83.8 (15.9)77.9 (16.7)
BMI (kg/m2), mean (SD)27.0 (6.0)27.7 (6.2)27.4 (6.2)28.1 (5.5)28.6 (5.4)26.5 (4.9)
Time since AS diagnosis (years), mean (SD)6.1 (8.6)3.7 (5.7)3.9 (6.2)8.5 (7.6)7.7 (9.0)10.2 (11.0)
Disease activity
 BASDAI, mean total score (SD)6.7 (1.4)6.4 (1.3)6.8 (1.3)6.5 (1.7)6.8 (1.2)6.7 (1.3)
 Total back pain (0–100 mm scale), mean score (SD)66.9 (15.4)63.2 (17.7)67.7 (17.7)65.2 (18.7)68.0 (17.5)71.6 (20.5)
 Patient’s global assessment of disease activity (0–100 mm scale), mean (SD)66.7 (15.9)60.1 (17.5)68.6 (15.8)68.6 (18.4)71.9 (16.3)73.5 (15.5)
 hsCRP (mg/L), mean (SD)23.8 (47.0)15.7 (20.1)16.6 (19.7)29.0 (55.3)14.7 (19.7)14.3 (16.6)
 ESR (mm/h), mean (SD)34.3 (24.1)28.2 (19.2)33.0 (15.5)33.3 (26.2)29.2 (23.1)24.2 (20.0)
 HLA-B27
  Negative8 (18.2)9 (20.0)8 (18.2)4 (14.3)6 (21.4)4 (14.3)
  Positive33 (75.0)32 (71.1)33 (75.0)24 (85.7)21 (75.0)24 (85.7)
  Missing3 (6.8)4 (8.9)3 (6.8)0 (0.0)1 (3.6)0 (0.0)
Previous treatment
 MTX use at randomisation6 (13.6)5 (11.1)4 (8.9)2 (7.1)4 (14.3)5 (17.2)
 Sulfasalazine use at randomisation4 (9.1)8 (17.8)9 (20.0)0 (0.0)6 (21.4)10 (11.8)
  • AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BMI, body mass index; ESR, erythrocyte sedimentation rate; HLA, human leukocyte antigen; hsCRP, high-sensitivity C-reactive protein; MTX, methotrexate; s.c., subcutaneously; TNF, tumour necrosis factor.